ResearcherPennsylvania State UniversityActive in the last 2 years
Chan Shen
Matched on ORCID iD 0000-0001-5680-3134; OpenAlex author ID A5029035012. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 2 papers
Papers 7
- Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB. First author DOI 10.1016/j.esmogo.2024.100049↗
- Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. Co-author DOI 10.1016/j.jss.2023.09.066↗
- Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. First author DOI 10.3390/cancers14020283↗
- Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. Co-author DOI 10.1002/jso.26481↗
- Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. Last author DOI 10.1245/s10434-020-09043-y↗
- ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathology. Last author DOI 10.1245/s10434-020-09079-0↗
- Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology. Co-author DOI 10.1245/s10434-020-09546-8↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elizabeth Josephine Olecki · 5 shared papers, 2021–2024 · strength 0.90
- Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
- Paper ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathol… DOI 10.1245/s10434-020-09079-0↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- June S. Peng · 4 shared papers, 2021–2024 · strength 0.68
- Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
- Matthew E. B. Dixon · 4 shared papers, 2021–2024 · strength 0.68
- Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
- Niraj Jaysukh Gusani · 4 shared papers, 2021 · strength 0.68
- Paper ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathol… DOI 10.1245/s10434-020-09079-0↗
- Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
- Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
- Michael Brian LaPelusa · 2 shared papers, 2022–2024 · strength 0.39
- Cathy Eng · 2 shared papers, 2022–2024 · strength 0.39
- Dana Backlund Cardin · 2 shared papers, 2022–2024 · strength 0.39
- Jordan D. Berlin · 2 shared papers, 2022–2024 · strength 0.39
- Madeline B. Torres · 2 shared papers, 2021 · strength 0.30
- Rajiv Agarwal · 1 shared paper, 2024 · strength 0.24
- Christopher Cann · 1 shared paper, 2024 · strength 0.24
- Marcus Chuan Beng Tan · 1 shared paper, 2022 · strength 0.15
- A. Bapsi Chakravarthy · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.